Moderation
Zeitpunkt: 07.08.14 10:06
Aktionen: Löschung des Beitrages, Thread geschlossen
Kommentar: Regelverstoß
Zeitpunkt: 07.08.14 10:06
Aktionen: Löschung des Beitrages, Thread geschlossen
Kommentar: Regelverstoß
Link: Nutzungsbedingungen
Anzeige
Meldung des Tages: Breaking News: Zweites VIVI-Produktionswerk eröffnet!
Löschung
Beiträge:
70
Zugriffe: 12.083 / Heute: 3
Zugriffe: 12.083 / Heute: 3
|
Gelöschter Beitrag.
Einblenden
»
#1
Werbung
Entdecke die beliebtesten ETFs von SPDR
warum wirst Du dem alten sräd untreu?
So neu sind die News ja nun wirklich nicht *g*
Gruss
RPM
So neu sind die News ja nun wirklich nicht *g*
Gruss
RPM
News verkündet, sondern will mit dem neuen Thread nur verdeutlichen, dass eine neue Ära in den kommenden Wochen/Monaten anbrechen wird.
Wenn man sich das letzte Interview von M. Ivezic anhört, wird man richtig angesteckt von seiner Euphorie. Er sieht zB. das AMEX-Listing und den damit verbundenen Kurs von mindestens 2 USD nur als Zwischenschritt zu weit höheren zukünftigen Kursen.
Er wird in nächster Zeit auch in China und Dubai mit Investorengruppen sprechen, und es gibt zu dem bereits gefundenen Pharmapartner noch weitere JV in Vorbereitung mit einigen global Playern.
Hier wird es bald richtig abgehen, da bin ich mir sicher :-)).
Wenn man sich das letzte Interview von M. Ivezic anhört, wird man richtig angesteckt von seiner Euphorie. Er sieht zB. das AMEX-Listing und den damit verbundenen Kurs von mindestens 2 USD nur als Zwischenschritt zu weit höheren zukünftigen Kursen.
Er wird in nächster Zeit auch in China und Dubai mit Investorengruppen sprechen, und es gibt zu dem bereits gefundenen Pharmapartner noch weitere JV in Vorbereitung mit einigen global Playern.
Hier wird es bald richtig abgehen, da bin ich mir sicher :-)).
Seit wann darf es nur einen Thread zu einem Wert geben ? Ausserdem habe ich die Eröffnung dieses Threads begründet.
Den alten Thread werde ich nun aus Protest nicht mehr benutzen, d.h. es wird nicht mehr viel an aktuellen Infos dort geposted werden.
Na ja, seinen Nick hat dieser Mod schon gut gewählt, hat wohl keine sonstigen Möglichkeiten sich zu profilieren :-(.
Den alten Thread werde ich nun aus Protest nicht mehr benutzen, d.h. es wird nicht mehr viel an aktuellen Infos dort geposted werden.
Na ja, seinen Nick hat dieser Mod schon gut gewählt, hat wohl keine sonstigen Möglichkeiten sich zu profilieren :-(.
Der arbeitet noch nicht so lange hier und ihm fehlt halt bisweilen noch das Feingefühl!
Aber ansonsten seh ich ihn nicht ohne Hoffnung und wenn er etwas routinierter ist und sich von mir etwas anleiten läßt, wird das schon noch!
Kein Sorge, ich hab ein Auge auf ihn!
LG Tony
Aber ansonsten seh ich ihn nicht ohne Hoffnung und wenn er etwas routinierter ist und sich von mir etwas anleiten läßt, wird das schon noch!
Kein Sorge, ich hab ein Auge auf ihn!
LG Tony
0,23 vor laaaaaaaanger Zeit
du wirst vielleicht doch noch der erste auf meiner Ignore-Liste werden :-).
Sei so gut und erspare mir deine nichtssagenden Kommentare, das darf nur mein Spezi buran.
@buran: ich hatte meinen Schnitt schon Mal geposted, der ist schön niedrig. In die rote Zone werde ich damit nicht mehr kommen, HSXI wird wohl mein 3. Tenbagger (oder mehr ?) werden *g*.
Sei so gut und erspare mir deine nichtssagenden Kommentare, das darf nur mein Spezi buran.
@buran: ich hatte meinen Schnitt schon Mal geposted, der ist schön niedrig. In die rote Zone werde ich damit nicht mehr kommen, HSXI wird wohl mein 3. Tenbagger (oder mehr ?) werden *g*.
gibt woanders so viele Prozente einzuheimseln ,Faulpelz ;-)
4 stellige Stückzahl zu 0,82 rein
4 stellige Stückzahl zu in Schnitt zu 0,05 raus
5 stellige Stückzahl zu 0,11 reis
5 stellige Stückzahl zu 0,209 rein
5 stellige Stückzahl zu 0,207 rein
und seither warten.
Derzeitiger realisierter Verlust 4 stellig vor und nach Steuer.
Ebenso buchmäßiger Verlust im 4 stelligen Bereich.
4 stellige Stückzahl zu in Schnitt zu 0,05 raus
5 stellige Stückzahl zu 0,11 reis
5 stellige Stückzahl zu 0,209 rein
5 stellige Stückzahl zu 0,207 rein
und seither warten.
Derzeitiger realisierter Verlust 4 stellig vor und nach Steuer.
Ebenso buchmäßiger Verlust im 4 stelligen Bereich.
5500 Stücke, hehehe. Gestern verkaufte einer 1K zu 0,186€. Manchmal kann ich nicht glauben, wie schlecht manche Leute informiert sind. Wir haben jetzt schon lange einen sehr stabilen Boden bei 25/26 US Cent, grosse Ereignisse stehen unmittelbar bevor und da verkauft einer seine Stücke, ein Umsatz von lächerlichen 186 Euro. Statt zu warten, bis er 1000 Euro für 1K Aktien bekommt. Die Zeit wird kommen :-).
Nur der starke Euro nervt mich, 1,40 jetzt geknackt - nun ist aber Mal gut :-((.
Datum Erster Hoch Tief Schluss Stücke
20.09.07 0,18 0,18 0,18 0,18 0
19.09.07 0,186 0,186 0,186 0,186 1.000
18.09.07 0,20 0,20 0,19 0,19 0
17.09.07 0,21 0,21 0,21 0,21 0
14.09.07 0,19 0,19 0,19 0,19 0
13.09.07 0,17 0,17 0,17 0,17 0
12.09.07 0,19 0,19 0,19 0,19 0
11.09.07 0,19 0,19 0,19 0,19 0
10.09.07 0,19 0,19 0,19 0,19 0
07.09.07 0,175 0,175 0,175 0,175 0
06.09.07 0,175 0,175 0,175 0,175 0
05.09.07 0,155 0,155 0,155 0,155 1.400
04.09.07 0,18 0,18 0,16 0,16 0
03.09.07 0,18 0,18 0,18 0,18 2.700
31.08.07 0,17 0,175 0,17 0,175 0
30.08.07 0,17 0,17 0,17 0,17 0
29.08.07 0,17 0,17 0,17 0,17 0
28.08.07 0,20 0,20 0,20 0,20 0
27.08.07 0,20 0,20 0,20 0,20 0
24.08.07 0,20 0,20 0,20 0,20 0
23.08.07 0,20 0,20 0,20 0,20 400
Nur der starke Euro nervt mich, 1,40 jetzt geknackt - nun ist aber Mal gut :-((.
Datum Erster Hoch Tief Schluss Stücke
20.09.07 0,18 0,18 0,18 0,18 0
19.09.07 0,186 0,186 0,186 0,186 1.000
18.09.07 0,20 0,20 0,19 0,19 0
17.09.07 0,21 0,21 0,21 0,21 0
14.09.07 0,19 0,19 0,19 0,19 0
13.09.07 0,17 0,17 0,17 0,17 0
12.09.07 0,19 0,19 0,19 0,19 0
11.09.07 0,19 0,19 0,19 0,19 0
10.09.07 0,19 0,19 0,19 0,19 0
07.09.07 0,175 0,175 0,175 0,175 0
06.09.07 0,175 0,175 0,175 0,175 0
05.09.07 0,155 0,155 0,155 0,155 1.400
04.09.07 0,18 0,18 0,16 0,16 0
03.09.07 0,18 0,18 0,18 0,18 2.700
31.08.07 0,17 0,175 0,17 0,175 0
30.08.07 0,17 0,17 0,17 0,17 0
29.08.07 0,17 0,17 0,17 0,17 0
28.08.07 0,20 0,20 0,20 0,20 0
27.08.07 0,20 0,20 0,20 0,20 0
24.08.07 0,20 0,20 0,20 0,20 0
23.08.07 0,20 0,20 0,20 0,20 400
warum das Eingangsposting gelöscht wurde. Angebliche Urheberrechtsverletzung, welche genau, mhm, wurde nicht mitgeteilt.
Ich hatte aus drei verschiedenen Quellen zitiert, denn etwas Info muss sein, sonst kann man sich postings bei Ariva sparen.
Wahrscheinlich hätte ich die Quellen nicht nennen sollen, dann wäre nix gelöscht worden....lol.
Ich hatte aus drei verschiedenen Quellen zitiert, denn etwas Info muss sein, sonst kann man sich postings bei Ariva sparen.
Wahrscheinlich hätte ich die Quellen nicht nennen sollen, dann wäre nix gelöscht worden....lol.
tatsächlich ein Umsatz von 7800 Stücken zu 0,185 - das sind mehr als in den gesamten letzten 4 Wochen, weiss da einer mehr *g* ??
Nächste Woche gibt es News, der Name des Pharmapartners wird öffentlich gemacht, dies versicherte M.Ivezic in einem Interview.
Auch sollten sich dann bald einige dicke Fische für das HSXI-Juwel interessieren, die können einige meiner shares kaufen, hehehe, aber nicht unter 1 EUR :-).
Nächste Woche gibt es News, der Name des Pharmapartners wird öffentlich gemacht, dies versicherte M.Ivezic in einem Interview.
Auch sollten sich dann bald einige dicke Fische für das HSXI-Juwel interessieren, die können einige meiner shares kaufen, hehehe, aber nicht unter 1 EUR :-).
Mein Brief liegt weiterhin bei 0,15 aus.
Und bei dem Volumen ist dies eine Barriere, stärker als jede Betonwand.
Die bewegt sich nicht einmal nach unten, wenn Du all deine Shares auf den Markt schmeissen würdest Matzel. *g*
Und bei dem Volumen ist dies eine Barriere, stärker als jede Betonwand.
Die bewegt sich nicht einmal nach unten, wenn Du all deine Shares auf den Markt schmeissen würdest Matzel. *g*
denke, dass du einen fetteren Köder als die mageren 0,15 EUR an den Haken hängen musst. Sieht so aus, als ob heute auch in USA nix geht, kein nennenswertes Volumen bisher.
Roadshow seit Dienstag und nächste Woche wird der 1. Pharmapartner genannt werden, das gibt viel PR in den Medien (auch bei grossen institutionellen Investoren).
Die Infomercials zu der 2.Generation des enSonix@home laufen Anfang Oktober an (5 Stück in 15sec/30sec/1min/10min/30min !!). Da frage ich mich, wo die 10 bzw. 30-Minuten Varianten laufen werden.
Mal schauen, wie der Kurs sich im 4. Quartal bis zum geplanten AMEX-Listing entwickelt :-).
Roadshow seit Dienstag und nächste Woche wird der 1. Pharmapartner genannt werden, das gibt viel PR in den Medien (auch bei grossen institutionellen Investoren).
Die Infomercials zu der 2.Generation des enSonix@home laufen Anfang Oktober an (5 Stück in 15sec/30sec/1min/10min/30min !!). Da frage ich mich, wo die 10 bzw. 30-Minuten Varianten laufen werden.
Mal schauen, wie der Kurs sich im 4. Quartal bis zum geplanten AMEX-Listing entwickelt :-).
bin ich für 4 Wochen unterwegs, werde aber regelmässig nach meinem Baby schauen. Wie man an dem Gesamtchart erkennen kann, ist noch sehr viel Luft nach oben. Die Situation seit Notierung zu Höchstkursen hat sich ja immens verbessert, alle vom Management angekündigten Schritte sind erfolgt und nun wird so langsam die Ernte eingefahren.
Den Miesepetruss habe ich als einzigen und ersten Kandidaten auf Ignore gesetzt, da er noch nie irgendeine konstruktive, sachlich begründete Kritik geäussert hat, nur schadenfrohes Blabla, und das möchte ich allen ersparen, die hier mitlesen und vielleicht noch Verluste mit sich herumschleppen.
Den Miesepetruss habe ich als einzigen und ersten Kandidaten auf Ignore gesetzt, da er noch nie irgendeine konstruktive, sachlich begründete Kritik geäussert hat, nur schadenfrohes Blabla, und das möchte ich allen ersparen, die hier mitlesen und vielleicht noch Verluste mit sich herumschleppen.
ich mach mir gerade wieder hoffnung,
auch wenn ich in meinen Börsendaten nie sehen kann, welche Barrieren bis zur 0,15 eingezogen sind.
Heute wurden die Barrieren bis 0,16 geknackt.
Jetzt seh ich noch eine Order bei 0,152 und bei 0,151 werden sicher auch noch welche kaufen wollen.
Aber darunter sollte dann mein Trade, zumindest anteilig gehandelt werden. ;o)
Wenn nicht, auch egal. Bin ja ausreichend investiert.
auch wenn ich in meinen Börsendaten nie sehen kann, welche Barrieren bis zur 0,15 eingezogen sind.
Heute wurden die Barrieren bis 0,16 geknackt.
Jetzt seh ich noch eine Order bei 0,152 und bei 0,151 werden sicher auch noch welche kaufen wollen.
Aber darunter sollte dann mein Trade, zumindest anteilig gehandelt werden. ;o)
Wenn nicht, auch egal. Bin ja ausreichend investiert.
fett dabei und das schon seit Monaten.Warten soll ja manchmal reichlichts entlohnt werden.;-)
leider hat der Kurs nachgegeben, nach kurzem Aufflackern. Sehr seltsam ist das schon.......wie lange noch ?
Sep 26, 2007 11:09 ET
HealthSonix and Abbott Laboratories Launch Innovative Combination Therapy Program for Patients With Advanced Rheumatoid Arthritis
Significant Development in the Fight Against Advanced Rheumatoid Arthritis
AquaSonix
IRVINE, CA--(Marketwire - September 26, 2007) - HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) announced today that the joint marketing program with Abbott Laboratories has commenced in Southern Ontario, Canada. The program is the first of its kind and offers Rheumatologists the option of prescribing \"combination therapy\" for patients with advanced rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
\"The guidelines published by the American College of Rheumatology [ACR] for rheumatoid arthritis state that \'the ultimate goals in managing RA are to prevent or control joint damage, prevent loss of function, and decrease pain,\'\" said Dieter D. Doederlein, Vice President Corporate Development of HealthSonix. \"To maintain joint function, the guidelines suggest that \'regular participation in dynamic and even aerobic conditioning exercise programs improves joint mobility, muscle strength, aerobic fitness and function, and psychological well being without increasing fatigue or joint symptoms.\' That is why the combination therapy now offered by Abbott Laboratories and HealthSonix is a significant new development for both rheumatologists and their patients,\" said Doederlein.
Abbott\'s biologic therapy works against the inflammatory process like other TNF blockers and has been shown to be effective in controlling symptoms of the disease. The product is indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.
The benefits of AquaSonix Therapy for the patient with immunological disorders include provision of a reduced weight-bearing environment in which to exercise; improvement in Range Of Motion; reduction in joint and muscle stiffness; improvement in the willingness to move; improvement in functional strength and functional mobility; improvement in social and psychological factors.
\"This new program represents a significant development in the fight against arthritis because the ACR guidelines stress that the combination of medications and non-pharmacological therapies is the optimal way to treat the patients,\" said Doederlein.
HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company. The Company\'s core products are based on proprietary, patent pending medical technologies that use sound pulses to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain. All pain relief treatments and products are safe, non-invasive, and have no known side effects.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Contact:
Dieter D. Doederlein
1-877-622-2121
Email Contact
Sep 26, 2007 11:09 ET
HealthSonix and Abbott Laboratories Launch Innovative Combination Therapy Program for Patients With Advanced Rheumatoid Arthritis
Significant Development in the Fight Against Advanced Rheumatoid Arthritis
AquaSonix
IRVINE, CA--(Marketwire - September 26, 2007) - HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) announced today that the joint marketing program with Abbott Laboratories has commenced in Southern Ontario, Canada. The program is the first of its kind and offers Rheumatologists the option of prescribing \"combination therapy\" for patients with advanced rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
\"The guidelines published by the American College of Rheumatology [ACR] for rheumatoid arthritis state that \'the ultimate goals in managing RA are to prevent or control joint damage, prevent loss of function, and decrease pain,\'\" said Dieter D. Doederlein, Vice President Corporate Development of HealthSonix. \"To maintain joint function, the guidelines suggest that \'regular participation in dynamic and even aerobic conditioning exercise programs improves joint mobility, muscle strength, aerobic fitness and function, and psychological well being without increasing fatigue or joint symptoms.\' That is why the combination therapy now offered by Abbott Laboratories and HealthSonix is a significant new development for both rheumatologists and their patients,\" said Doederlein.
Abbott\'s biologic therapy works against the inflammatory process like other TNF blockers and has been shown to be effective in controlling symptoms of the disease. The product is indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.
The benefits of AquaSonix Therapy for the patient with immunological disorders include provision of a reduced weight-bearing environment in which to exercise; improvement in Range Of Motion; reduction in joint and muscle stiffness; improvement in the willingness to move; improvement in functional strength and functional mobility; improvement in social and psychological factors.
\"This new program represents a significant development in the fight against arthritis because the ACR guidelines stress that the combination of medications and non-pharmacological therapies is the optimal way to treat the patients,\" said Doederlein.
HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company. The Company\'s core products are based on proprietary, patent pending medical technologies that use sound pulses to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain. All pain relief treatments and products are safe, non-invasive, and have no known side effects.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Contact:
Dieter D. Doederlein
1-877-622-2121
Email Contact
vielleicht kriegst du deine Shares zu 0,15 doch noch. Ich kaufe ab 0,12 dann wieder ein, hehehe.
Interessant, wie der Kurs auf die JV-Meldung reagiert hat, das lässt tief blicken....
Interessant, wie der Kurs auf die JV-Meldung reagiert hat, das lässt tief blicken....
Eigentlich wünsche ich Dir und mir in dieser Situation kein Glück, was Zukäufe betrifft.
Lieber hätte ich schon jetzt den Ausbruch nach oben gesehen! ;o)
Lieber hätte ich schon jetzt den Ausbruch nach oben gesehen! ;o)
Bin mit der großen Order raus und hab nur noch 10.000 genommen.
Muss mich ja nicht unbedingt über Pari bedienen lassen.
Wurde gestern eigentlich in Frankfurt gehandelt?
Bei mir steht 100 Stück Umsatz am 03.10.07.
Dachte gestern war zu wegen Feiertag.
Muss mich ja nicht unbedingt über Pari bedienen lassen.
Wurde gestern eigentlich in Frankfurt gehandelt?
Bei mir steht 100 Stück Umsatz am 03.10.07.
Dachte gestern war zu wegen Feiertag.
aber hier bei Healthsonix sind andere Öffnungszeiten der Fall.Schläft seit Monaten tief und fest.Fest ist gut ,wenn das Teil wieder in den Wind stechen tut.Dann gibbet wieder 'ne Sause sondergleichens.:-)
und irgendwann kommt die Zündung und der Kurs geht ab......(ich habe die Creme auch selber in Gebrauch und sie wirkt sehr gut gegen meinen "Golfarm", der mir momentan keine Probleme mehr macht).
Seid gegrüsst aus dem Urlaub, RPM und Buran, freut mich, dass ihr nicht auch eure shares verramscht.
IRVINE, CA, Oct 04, 2007 (MARKET WIRE via COMTEX)
HealthSonix, Inc.(PINKSHEETS: HSXI) (FRANKFURT: H7S) today announced that it has launched a major Media campaign in North America for ZingiberRx through Synergy Management Group.
This comprehensive media blitz has been aimed at a cross-section of media,
including wellness, health, general interest, sports, travel, seniors medical,
and other special interest magazines, as well as internet vehicles, general
newspapers and magazines, TV and community newspapers.
"The word is out," said Jay Silverberg, of Synergy Management Group. "The
reaction from the media marketplace is exceptional. It seems that ZingiberRX is
generating interest and excitement. Positioned between prescription medication
and all those traditional, staid, over-the-counter products, ZingiberRX is an
exciting alternative that is being recognized by the media, and wellness /
health care providers."
"We have already received numerous call backs requesting more information and
samples resulting from this effort, which only started last week," said Dieter
D. Doederlein, Vice President Corporate Development for HealthSonix. "It seems
that a common thread is the efficacy and affordability of our product,
particularly for the 47 million American citizens who cannot afford medical
insurance," he added.
"We feel that HealthSonix has medical products that will have a worldwide
impact, and the initial response to our program is confirmation," said Jay
Silverberg, President & CEO, Synergy Management Group Ltd. "In our experience,
products that will have an impact usually capture the media's attention at an
early stage," said Mr. Silverberg.
Customers can order ZingiberRx online at www.myarthritisstore.com, or by calling
the Company toll-free line at 1-877-622-2121. Affordably priced at $24.95 per
tube, ZingiberRx comes in 80 gram tubes, which will typically provide a month of
pain relief.
Seid gegrüsst aus dem Urlaub, RPM und Buran, freut mich, dass ihr nicht auch eure shares verramscht.
IRVINE, CA, Oct 04, 2007 (MARKET WIRE via COMTEX)
HealthSonix, Inc.(PINKSHEETS: HSXI) (FRANKFURT: H7S) today announced that it has launched a major Media campaign in North America for ZingiberRx through Synergy Management Group.
This comprehensive media blitz has been aimed at a cross-section of media,
including wellness, health, general interest, sports, travel, seniors medical,
and other special interest magazines, as well as internet vehicles, general
newspapers and magazines, TV and community newspapers.
"The word is out," said Jay Silverberg, of Synergy Management Group. "The
reaction from the media marketplace is exceptional. It seems that ZingiberRX is
generating interest and excitement. Positioned between prescription medication
and all those traditional, staid, over-the-counter products, ZingiberRX is an
exciting alternative that is being recognized by the media, and wellness /
health care providers."
"We have already received numerous call backs requesting more information and
samples resulting from this effort, which only started last week," said Dieter
D. Doederlein, Vice President Corporate Development for HealthSonix. "It seems
that a common thread is the efficacy and affordability of our product,
particularly for the 47 million American citizens who cannot afford medical
insurance," he added.
"We feel that HealthSonix has medical products that will have a worldwide
impact, and the initial response to our program is confirmation," said Jay
Silverberg, President & CEO, Synergy Management Group Ltd. "In our experience,
products that will have an impact usually capture the media's attention at an
early stage," said Mr. Silverberg.
Customers can order ZingiberRx online at www.myarthritisstore.com, or by calling
the Company toll-free line at 1-877-622-2121. Affordably priced at $24.95 per
tube, ZingiberRx comes in 80 gram tubes, which will typically provide a month of
pain relief.
Jetzt da wo wir so lange ausgeharrt haben und uns niederträchtige Postings reinziehen mussten werden wir uns den sicheren Sieg doch nicht mehr nehmen lassen.Standfest bleiben und wir werden reich belohnt werden.;-)
Dein Wort in meiner Bierpulle na dann muss et ja watt werden lach
Woher hasst Du die Pressemitteilungen, bevor sie auf der HP von HS stehen?
Die vom 04.10.07 habe ich erst heute auf der HP gefunden.
Gruss
RPM
Die vom 04.10.07 habe ich erst heute auf der HP gefunden.
Gruss
RPM
die aktuellen Pressemeldungen findest du zB. auf Yahoo (Symbol HSXI.PK, dort unter Headlines):
finance.yahoo.com/q?s=HSXI.PK
Die HP von HSXI ist da nicht aktuell. So langsam scheint das Volumen auch in USA gegen Null zu gehen, wird auch Zeit, bei diesen Kursen.
finance.yahoo.com/q?s=HSXI.PK
Die HP von HSXI ist da nicht aktuell. So langsam scheint das Volumen auch in USA gegen Null zu gehen, wird auch Zeit, bei diesen Kursen.
mit MCNL.PK, die nach der Meldung über den Start eines infomercials im TV, eine Kurssteigerung um 800% hatten:
finance.yahoo.com/q?s=mncl.pk
Diese Firma vertreibt Wellness-Produkte (Pillen aus Naturwirkstoffen), unter anderem auch für Arthritis-Beschwerden. Der Nachweis der Wirksamkeit wird über Studien des Firmengründers Dr.Martin erbracht (hehehe).
Das kann man jetzt werten, wie man will, ich erwähne dies nur, um das Potenzial von HSXI aufzuzeigen, wenn es losgeht, dann vielleicht wie bei MCLN - Vormeldungs-SK war bei 0,0002 und der Eröffnungskurs am nächsten Tag bei 0,005 - da hatten die Makler aber zu hoch gegriffen und der SK war dann bei 0,0018.
Im Vergleich erscheinen mir die Produkte von HSXI dann doch überlegen (seriöser) zu sein, ganz abgesehen von dem 1. namhaften Partner Abbott, denn die hätten sich auch bei MCNL engagieren können.
finance.yahoo.com/q?s=mncl.pk
Diese Firma vertreibt Wellness-Produkte (Pillen aus Naturwirkstoffen), unter anderem auch für Arthritis-Beschwerden. Der Nachweis der Wirksamkeit wird über Studien des Firmengründers Dr.Martin erbracht (hehehe).
Das kann man jetzt werten, wie man will, ich erwähne dies nur, um das Potenzial von HSXI aufzuzeigen, wenn es losgeht, dann vielleicht wie bei MCLN - Vormeldungs-SK war bei 0,0002 und der Eröffnungskurs am nächsten Tag bei 0,005 - da hatten die Makler aber zu hoch gegriffen und der SK war dann bei 0,0018.
Im Vergleich erscheinen mir die Produkte von HSXI dann doch überlegen (seriöser) zu sein, ganz abgesehen von dem 1. namhaften Partner Abbott, denn die hätten sich auch bei MCNL engagieren können.
Matzelbub, gibt es irgendeinen Termin, wo Healthsonix mal etwas reportet.
Quartalszahlen, Jahresbericht oder eine HV?
Quartalszahlen, Jahresbericht oder eine HV?
eine Pinksheet company ist an keine Berichtspflichten gebunden. HSXI will/muss bis Jahresende im Zuge des angestrebten AMEX-Listings einen Finanzbericht abgeben.
Die werden das so lange wie möglich hinauszögern, könnte mir auch vorstellen, dass es erst im neuen Jahr soweit ist. Lassen wir uns überraschen......
Hier ein aktuelles Statement vom Green Baron:
From the Green Baron (Friday 10/12/2007)
Focus Pick Update
HealthSonix, Inc. (OTCPK: HSXI)
Special offer to Green Baron Members
HealthSonix (HSXI) has initially (and we believe temporarily) struggled to gain traction following an announcement that the company and Abbott Laboratories would launch an innovative combination therapy program for patients with advanced rheumatoid arthritis. As we all know, one of the most significant and opportunistic PR's any company can release is one that contains an association with a household name. (in this case Abbott Laboratories). Not only does the company announcing the major PR get the chance to excite it's current shareholders with a potentially huge new development but it also gets the unique opportunity to create exposure for itself among the shareholders of the household name company. Two for the price of one so to speak. In our opinion one reason this highly anticipated union seems off to a bit of a slow start is because the program is only commencing in Southern Ontario. So give it some time. Think of it this way; What if one of the largest auto makers in the world suddenly created an association with a much smaller auto maker. What would an investor expect the share price of the smaller company to do as a result? Therefore, The Green Baron Report still believes HealthSonix has a focused plan that involves significant and increased marketing initiatives as well as exciting new collaborations.
The management of HealthSonix is currently offering members of The Green Baron Report the opportunity to receive a free sample of its ZingiberRx joint and muscle pain relieving cream. To order, simply call (877) 622-2121 or send an email with your contact information to info@healthsonix.com. We have been instructed that you will receive a free sample in the mail. This shows how much confidence HealthSonix has in it's product and how much they value the involvement and support of our Green Baron members. Yet another feather in The Green Baron's cap!
Die werden das so lange wie möglich hinauszögern, könnte mir auch vorstellen, dass es erst im neuen Jahr soweit ist. Lassen wir uns überraschen......
Hier ein aktuelles Statement vom Green Baron:
From the Green Baron (Friday 10/12/2007)
Focus Pick Update
HealthSonix, Inc. (OTCPK: HSXI)
Special offer to Green Baron Members
HealthSonix (HSXI) has initially (and we believe temporarily) struggled to gain traction following an announcement that the company and Abbott Laboratories would launch an innovative combination therapy program for patients with advanced rheumatoid arthritis. As we all know, one of the most significant and opportunistic PR's any company can release is one that contains an association with a household name. (in this case Abbott Laboratories). Not only does the company announcing the major PR get the chance to excite it's current shareholders with a potentially huge new development but it also gets the unique opportunity to create exposure for itself among the shareholders of the household name company. Two for the price of one so to speak. In our opinion one reason this highly anticipated union seems off to a bit of a slow start is because the program is only commencing in Southern Ontario. So give it some time. Think of it this way; What if one of the largest auto makers in the world suddenly created an association with a much smaller auto maker. What would an investor expect the share price of the smaller company to do as a result? Therefore, The Green Baron Report still believes HealthSonix has a focused plan that involves significant and increased marketing initiatives as well as exciting new collaborations.
The management of HealthSonix is currently offering members of The Green Baron Report the opportunity to receive a free sample of its ZingiberRx joint and muscle pain relieving cream. To order, simply call (877) 622-2121 or send an email with your contact information to info@healthsonix.com. We have been instructed that you will receive a free sample in the mail. This shows how much confidence HealthSonix has in it's product and how much they value the involvement and support of our Green Baron members. Yet another feather in The Green Baron's cap!
buran ,was macht die Healthsonix?
... ach wissen sie ,Healthsonix schmiert mir jeden Tag weiter ab:-(
... ach wissen sie ,Healthsonix schmiert mir jeden Tag weiter ab:-(
dann mach doch Mal einen Stützungskauf......
aber hast schon Recht, das ist ja nicht mehr zum Aushalten langsam mit dem Kurs.
aber hast schon Recht, das ist ja nicht mehr zum Aushalten langsam mit dem Kurs.
von HSXI seit dem 04. Oktober.
Es gibt eine Verzögerung des Produktionsstartes der 2. Generation des enSonix@home Gerätes, wegen eines Fehlers im Display.
Deshalb laufen die Infomercials nicht wie geplant an.
Solche Verzögerungen sind nicht ungewöhnlich, das weiss jeder, der einmal für einen Hersteller von elektronischen Geräten tätig war. Erst wenn die Qualität 100% in Ordnung ist, wird produziert.
Ansonsten ist man schnell pleite als kleine Firma.
Ich jedenfalls bin meine Schmerzen im Ellbogen durch die ZingiberRX Creme los, seit nunmehr ca. 4 Wochen. Das ist schon erstaunlich, wenn ich bedenke, wie lange ich damit zu tu hatte und wie schnell die Behandlung erfolgreich war.
Jetzt hoffe ich, dass ich noch Mal billig Shares kaufen kann :-).
Es gibt eine Verzögerung des Produktionsstartes der 2. Generation des enSonix@home Gerätes, wegen eines Fehlers im Display.
Deshalb laufen die Infomercials nicht wie geplant an.
Solche Verzögerungen sind nicht ungewöhnlich, das weiss jeder, der einmal für einen Hersteller von elektronischen Geräten tätig war. Erst wenn die Qualität 100% in Ordnung ist, wird produziert.
Ansonsten ist man schnell pleite als kleine Firma.
Ich jedenfalls bin meine Schmerzen im Ellbogen durch die ZingiberRX Creme los, seit nunmehr ca. 4 Wochen. Das ist schon erstaunlich, wenn ich bedenke, wie lange ich damit zu tu hatte und wie schnell die Behandlung erfolgreich war.
Jetzt hoffe ich, dass ich noch Mal billig Shares kaufen kann :-).
Bei mir steht jetzt erst wieder ein Boden bei 0,03 EUR an.
Der Verkaufsdruck wird massiv und keiner will das Papier mehr haben.
Keine Empfehlung
Der Verkaufsdruck wird massiv und keiner will das Papier mehr haben.
Keine Empfehlung
weitere 10K zu 0,11 EUR bekommen, allerdings wird mein Kauf bei Ariva nicht angezeigt ??
Meine nächste Order steht bei 0,085 EUR. Leider kann ich in USA nicht ordern, obwohl ich schon andere US-Werte (OTC sowie Pinksheets) dort geordert habe, bei HSXI geht das nicht, sonst hätte ich gestern ein paar mehr gekauft.
Keiner will das Papier mehr haben ?? Ich schon, vor allem wenn es so günstig ist.
Meine nächste Order steht bei 0,085 EUR. Leider kann ich in USA nicht ordern, obwohl ich schon andere US-Werte (OTC sowie Pinksheets) dort geordert habe, bei HSXI geht das nicht, sonst hätte ich gestern ein paar mehr gekauft.
Keiner will das Papier mehr haben ?? Ich schon, vor allem wenn es so günstig ist.
HealthSonix Announces Expansion in Florida
via COMTEX
October 31, 2007
IRVINE, CA, Oct 31, 2007 (MARKET WIRE via COMTEX News Network) --
HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) today announced that it is has selected a prestigious medical center in Boca Raton, Florida, for the first location of its specialty Arthritis Treatment Centers of America [ATCA]. The grand opening is scheduled for the spring of 2008.
The Arthritis Treatment Centers utilize the most advanced, non-invasive medical technologies and combine them with the best of the established therapies to reduce and even eliminate arthritis pain and restore joint mobility. The current treatment programs have exceptional success rates: 4 out of 5 patients report significant pain reduction in addition to greater mobility, more energy, and improved sleep.
ATCA follows the guidelines published by the American College of Rheumatology which recommend the use of nonpharmacologic therapies as a first line of defense. ATCA practices an integrated approach to arthritis care and the Centers are staffed with healthcare professionals from many of the medical disciplines required to address arthritis: Physical and Occupational Therapy; Rheumatology Rehabilitation; Kinesiology; Psychology; and Nutrition.
"In our facilities we promote wellness through a warm and welcoming environment. Our patients have helped us design many of the amenities that make each visit a pleasant and rewarding experience," stated Dieter D. Doederlein, Vice President of Corporate Development at HealthSonix. "With this new state of the art facility we'll be able to effectively service patients in the Palm Beach County. The new center will also double as a showcase facility and a training center for the South East United States. Arthritis is a number one source of pain in the world and population profile in South East Florida fits with the type of demographics we target with our treatments," added Doederlein.
HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company, engaged in the development, manufacture, and sale of proprietary medical products and biotechnologies that provide pain relief and muscle stimulation for people with osteoarthritis, rheumatoid arthritis, fibromyalgia, and musculoskeletal conditions related to muscle injuries -- essentially medical conditions where acute and chronic pain, muscle stiffness, poor circulation, and diminishing flexibility are among the underlying symptoms. The company's integrated portfolio of Food and Drug Administration ("FDA") registered products currently in the commercial marketplace includes: enSonix@home; AquaSonix Therapy; enSonixPro; and ZingiberRx pain relieving cream.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Contact:Dieter D. Doederlein1-877-622-2121Email Contact
SOURCE: HealthSonix, Inc.
www2.marketwire.com/mw/emailprcntct?id=0172266E1F5D7CF0
Copyright 2007 Market Wire, All rights reserved.
via COMTEX
October 31, 2007
IRVINE, CA, Oct 31, 2007 (MARKET WIRE via COMTEX News Network) --
HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) today announced that it is has selected a prestigious medical center in Boca Raton, Florida, for the first location of its specialty Arthritis Treatment Centers of America [ATCA]. The grand opening is scheduled for the spring of 2008.
The Arthritis Treatment Centers utilize the most advanced, non-invasive medical technologies and combine them with the best of the established therapies to reduce and even eliminate arthritis pain and restore joint mobility. The current treatment programs have exceptional success rates: 4 out of 5 patients report significant pain reduction in addition to greater mobility, more energy, and improved sleep.
ATCA follows the guidelines published by the American College of Rheumatology which recommend the use of nonpharmacologic therapies as a first line of defense. ATCA practices an integrated approach to arthritis care and the Centers are staffed with healthcare professionals from many of the medical disciplines required to address arthritis: Physical and Occupational Therapy; Rheumatology Rehabilitation; Kinesiology; Psychology; and Nutrition.
"In our facilities we promote wellness through a warm and welcoming environment. Our patients have helped us design many of the amenities that make each visit a pleasant and rewarding experience," stated Dieter D. Doederlein, Vice President of Corporate Development at HealthSonix. "With this new state of the art facility we'll be able to effectively service patients in the Palm Beach County. The new center will also double as a showcase facility and a training center for the South East United States. Arthritis is a number one source of pain in the world and population profile in South East Florida fits with the type of demographics we target with our treatments," added Doederlein.
HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company, engaged in the development, manufacture, and sale of proprietary medical products and biotechnologies that provide pain relief and muscle stimulation for people with osteoarthritis, rheumatoid arthritis, fibromyalgia, and musculoskeletal conditions related to muscle injuries -- essentially medical conditions where acute and chronic pain, muscle stiffness, poor circulation, and diminishing flexibility are among the underlying symptoms. The company's integrated portfolio of Food and Drug Administration ("FDA") registered products currently in the commercial marketplace includes: enSonix@home; AquaSonix Therapy; enSonixPro; and ZingiberRx pain relieving cream.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Contact:Dieter D. Doederlein1-877-622-2121Email Contact
SOURCE: HealthSonix, Inc.
www2.marketwire.com/mw/emailprcntct?id=0172266E1F5D7CF0
Copyright 2007 Market Wire, All rights reserved.
da wird eine ganz unspektakuläre PR rausgegeben, diese Eröffnung des 1. US-Arthritiscenters in Florida war ja schon bekanntgegeben, ist Teil des Geschäftsplanes von HSXI.
Da flippen die Amis plötzlich aus und kaufen wie verrückt, so dass der Kurs unter hohem Volumen in der Spitze um über 100% zulegt.
Also wer es immer noch nicht glauben will, das ist ein weiteres Zeichen für das gewaltige Potenzial dieser Firma. Es werden noch wesentlich interessantere Meldungen kommen, auch das Interesse in D wird sich steigern.
Da flippen die Amis plötzlich aus und kaufen wie verrückt, so dass der Kurs unter hohem Volumen in der Spitze um über 100% zulegt.
Also wer es immer noch nicht glauben will, das ist ein weiteres Zeichen für das gewaltige Potenzial dieser Firma. Es werden noch wesentlich interessantere Meldungen kommen, auch das Interesse in D wird sich steigern.
(Verkleinert auf 80%) 
auch in D richtig Volumen reinkommt und der Kurs über 1 EUR geht. 50 cent bis Jahresende wären auch schon OK.
Healthsonix durchbrochen.Den Kurs noch ein wenig höher und ich fahre wieder mit gutem Plus daher.:-)
der Produktion des enSonix@home Gerätes 2.Generation und auf die Infomercials dazu, das wird einen Schub geben.
Richtig los geht es allerdings erst, wenn der erste Finanzbericht rauskommt, je länger man damit wartet, umso mehr Umsatz kann natürlich mit einbezogen werden....
Ich freue mich über weitere billige shares, wie diese Woche, denn es kann durchaus wieder schnell absacken - solange HSXI in den Pinksheets notiert.
Richtig los geht es allerdings erst, wenn der erste Finanzbericht rauskommt, je länger man damit wartet, umso mehr Umsatz kann natürlich mit einbezogen werden....
Ich freue mich über weitere billige shares, wie diese Woche, denn es kann durchaus wieder schnell absacken - solange HSXI in den Pinksheets notiert.
ich glauge zu sagen dass der Kurs spätestens nächste Woche bereits bei min. 25 Cent stehen sollte.Alle warten auf Ahnungsscheine und das spiegelt sich bereits jetzt schon im Kurs wieder.Also ,die 0,25 werden bald geknackt sein ,so meine Vermutung.
ich persönlich ließ die Hoffnung fahren, das es bis zu der Veröffentlichung der Geschäftszahlen nachhaltig nach oben geht.
Heißt aber nur, das ich meine Haltezeiten der Shares erhöhe und nicht, da ich Scheine abgeben werde.
Einmal kommt die Selbstdartellung über Cristian Radio von Döderlein und der Schein zieht innerhalb 2 Wochen um 1500% an und fällt dann wie ein bleierner Stein nach unten. Nun zieht die Marktwire Veröffentlichung (nicht einmal News) den Kurs an einem Tag von 0,13 auf 0,28 um dann wieder bei Boden 0,20 zu pendeln.
Nun sind wir doch alle darauf eingestellt billig einzusammeln. Zu Brief (über pari) USA nimmt doch keiner mehr was mit.
Einen Run wie bei den 0,45 seh ich nicht noch einmal vor Veröffentlichung der Geschäftszahlen am Jahresende. Aber ich als gebranntes Kind, scheue da eh das Feuer.
Bin einmal in die Bullenfalle getappt.
Bei 0,34 USD zu 0,21 EUR kaufen zu können, sah ich als tolle Sache an. Nochmal lauf ich nicht mehr ins offene Messer.
Gruss
RPM
Heißt aber nur, das ich meine Haltezeiten der Shares erhöhe und nicht, da ich Scheine abgeben werde.
Einmal kommt die Selbstdartellung über Cristian Radio von Döderlein und der Schein zieht innerhalb 2 Wochen um 1500% an und fällt dann wie ein bleierner Stein nach unten. Nun zieht die Marktwire Veröffentlichung (nicht einmal News) den Kurs an einem Tag von 0,13 auf 0,28 um dann wieder bei Boden 0,20 zu pendeln.
Nun sind wir doch alle darauf eingestellt billig einzusammeln. Zu Brief (über pari) USA nimmt doch keiner mehr was mit.
Einen Run wie bei den 0,45 seh ich nicht noch einmal vor Veröffentlichung der Geschäftszahlen am Jahresende. Aber ich als gebranntes Kind, scheue da eh das Feuer.
Bin einmal in die Bullenfalle getappt.
Bei 0,34 USD zu 0,21 EUR kaufen zu können, sah ich als tolle Sache an. Nochmal lauf ich nicht mehr ins offene Messer.
Gruss
RPM
hab's mir dreimal gaaanz langsam durchgelesen und sag' mal ja dazu.
Hinzufügend sei noch was zur Charttechnik gesagt.Sieht identisch zu der Entwicklung wie April diesen Jahres aus.Also wenn einer mich fragt wo denn die nächste Bullen getrieben werden ,dann hier ,buran
Hinzufügend sei noch was zur Charttechnik gesagt.Sieht identisch zu der Entwicklung wie April diesen Jahres aus.Also wenn einer mich fragt wo denn die nächste Bullen getrieben werden ,dann hier ,buran
dass M.Ivezic am Freitag von einer Geschäftsreise nach Europa und dem Nahen Osten zurückgekommen ist, vielleicht gibt es bald wieder News.....
Habe aber nichts gegen einen vorläufigen weiteren Kursverfall, kaufe gerne noch mehr billige Aktien, hehehe.
Habe aber nichts gegen einen vorläufigen weiteren Kursverfall, kaufe gerne noch mehr billige Aktien, hehehe.
Das ist ja mehr an den Deutschen Börsen als die ganze letzte Woche.
Jetzt geht sie aber ab wie Schmidts Katze. *lol*
Jetzt geht sie aber ab wie Schmidts Katze. *lol*
Klassenziel verfehlt, mein Kursziel war 0,50 USD bis Jahresende, wird wohl nix draus :-(.
Keine PR seit dem 31.10.07, der angekündigte Start von Infomercials und Produktion des Gen2 Modells ist ausgeblieben. Die Firma hat sich jetzt in einer eMail an die Shareholder gemeldet, wer den Text noch nicht kennt:
**************************
Here's an update sent out to known HSXI shareholders from Investor Relations at Health Sonix. Looking good for 2008.
Many shareholders have been calling/sending emails wondering why there has been no news for HSXI. I can assure you that management continues to move forward on many fronts, and we look forward to a break out year in 2008. The following captures the essence of most of your enquiries and provides answers:
1. The enSonix@home device has been undergoing QC testing for efficacy, overall performance and durability over the past 3 months and has now been cleared on the main functions for production. Engineering had suggested additional, minor improvements in some of the features and these have been incorporated. Finished production units are expected in February 2008.
2. The infomercial for the enSonix@home unit is essentially complete: the product beauty shots will be completed upon receipt of the finished enSonix@home device.
3. Marketing has recommended that the launch of the infomercial be delayed until February 2008 as the television clutter at this time of year would make it more challenging.
4. Management has scheduled additional meetings in Dubai to address the high level of interest in our products for distribution in the Middle East.
5. The IR meetings in New York have been progressing and 3rd round meetings have been scheduled for next week. HealthSonix expects to announce the selection of one or two institutions to work with the company on its financial planning and application to move to a more senior exchange within the next 2 weeks.
6. The ZingiberRx sampling program has yielded excellent results and several retail listing test markets are underway. A dedicated web site for the cream is almost complete and will go live within 10 days.
7. We are currently concentrating on the ZingiberRx cream and the take home unit as they offer the most immediate sales and profits; however, the AquaSonix and Treatment Centers are still very much part of our long range planning.
Trust the above addresses most of your inquiries, and we thank you for your continued support.
Keine PR seit dem 31.10.07, der angekündigte Start von Infomercials und Produktion des Gen2 Modells ist ausgeblieben. Die Firma hat sich jetzt in einer eMail an die Shareholder gemeldet, wer den Text noch nicht kennt:
**************************
Here's an update sent out to known HSXI shareholders from Investor Relations at Health Sonix. Looking good for 2008.
Many shareholders have been calling/sending emails wondering why there has been no news for HSXI. I can assure you that management continues to move forward on many fronts, and we look forward to a break out year in 2008. The following captures the essence of most of your enquiries and provides answers:
1. The enSonix@home device has been undergoing QC testing for efficacy, overall performance and durability over the past 3 months and has now been cleared on the main functions for production. Engineering had suggested additional, minor improvements in some of the features and these have been incorporated. Finished production units are expected in February 2008.
2. The infomercial for the enSonix@home unit is essentially complete: the product beauty shots will be completed upon receipt of the finished enSonix@home device.
3. Marketing has recommended that the launch of the infomercial be delayed until February 2008 as the television clutter at this time of year would make it more challenging.
4. Management has scheduled additional meetings in Dubai to address the high level of interest in our products for distribution in the Middle East.
5. The IR meetings in New York have been progressing and 3rd round meetings have been scheduled for next week. HealthSonix expects to announce the selection of one or two institutions to work with the company on its financial planning and application to move to a more senior exchange within the next 2 weeks.
6. The ZingiberRx sampling program has yielded excellent results and several retail listing test markets are underway. A dedicated web site for the cream is almost complete and will go live within 10 days.
7. We are currently concentrating on the ZingiberRx cream and the take home unit as they offer the most immediate sales and profits; however, the AquaSonix and Treatment Centers are still very much part of our long range planning.
Trust the above addresses most of your inquiries, and we thank you for your continued support.
dass hier im September die Hölle los sein sollte.Und?Wir schreiben mittlerweile Dezember.
jetzt können wir nur hoffen, dass es mit dem Februar klappt, denn es hängt viel von dem Verkaufsstart des enSonix Gen2 Modell ab. Das ist kurz/mittelfristig der grösste Umsatzbringer.
Die Zingiber-Creme scheint gut zu laufen und der Antrag auf einen Segmentwechsel wird jetzt auch in Angriff genommen. Dazu müsste es auch irgendwann Zahlen geben, dann werden wir sehen, was geht.
Die Zingiber-Creme scheint gut zu laufen und der Antrag auf einen Segmentwechsel wird jetzt auch in Angriff genommen. Dazu müsste es auch irgendwann Zahlen geben, dann werden wir sehen, was geht.
schreib nicht so viel Quark. Bestell dir lieber Mal so ein enSonix Gerät oder die ZingiberRx Salbe. Das hilft bei Schmerzen.
Also da hat einer seine 9K zu 0,045 geschmissen. Der Kurs wird aber in USA gemacht und hält sich noch.
Es wird bald wieder gute News geben, dann erholt sich der Kurs auch wieder.
Also da hat einer seine 9K zu 0,045 geschmissen. Der Kurs wird aber in USA gemacht und hält sich noch.
Es wird bald wieder gute News geben, dann erholt sich der Kurs auch wieder.
könnte langsam überwunden sein, heute bei überdurchschnittlichem Volumen ein schönes Plus in USA. Könnte auf baldige News hindeuten.....
(Verkleinert auf 80%)
HealthSonix Launches www.ZingiberRx.com to Increase Online Presence
Tuesday February 5, 8:00 am ET
IRVINE, Calif.--(BUSINESS WIRE)--HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) today announced that it has launched a dedicated web site for its ZingiberRx Joint and Muscle cream: www.ZingiberRx.com
ZingiberRx joint and muscle cream is fast acting, non-staining, fast absorbing, and deep penetrating. Unlike most over-the-counter topical ointments, ZingiberRx is not a counter-irritant and does not create a hot or a cold sensation when applied.
Medical research studies into the medicinal properties of various plants in the ginger (Zingiberaceae) family have isolated the Zingiber cassumunar and Zingiber officinale species for their anti-inflammatory, anti-allergic and pain relieving properties.
“The launch of this web site coincides with on going retail sampling and couponing programs being tested in major pharmacy chains.” said Dieter Doederlein, Vice President Corporate Development of HealthSonix. “The response to this new pain relieving cream, the first of its kind with ginger, continues to be very positive. We continue being a best selling topical pain reliever at those locations. “
The Company is also launching a major online sales and marketing campaign with Google and Yahoo adwords and banner ads on websites that cater to the 50+ population segment: “This new marketing program has been designed to increase awareness and promote direct to consumer sales from our online store.” added Doederlein.
HealthSonix, Inc. (OTC:HSXI - News)(FWB:H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The company’s patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Contact:
for HealthSonix, Inc.
Dieter Doederlein, 1-877-622-2121 x112
--------------------------------------------------
Source: HealthSonix, Inc.
Tuesday February 5, 8:00 am ET
IRVINE, Calif.--(BUSINESS WIRE)--HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) today announced that it has launched a dedicated web site for its ZingiberRx Joint and Muscle cream: www.ZingiberRx.com
ZingiberRx joint and muscle cream is fast acting, non-staining, fast absorbing, and deep penetrating. Unlike most over-the-counter topical ointments, ZingiberRx is not a counter-irritant and does not create a hot or a cold sensation when applied.
Medical research studies into the medicinal properties of various plants in the ginger (Zingiberaceae) family have isolated the Zingiber cassumunar and Zingiber officinale species for their anti-inflammatory, anti-allergic and pain relieving properties.
“The launch of this web site coincides with on going retail sampling and couponing programs being tested in major pharmacy chains.” said Dieter Doederlein, Vice President Corporate Development of HealthSonix. “The response to this new pain relieving cream, the first of its kind with ginger, continues to be very positive. We continue being a best selling topical pain reliever at those locations. “
The Company is also launching a major online sales and marketing campaign with Google and Yahoo adwords and banner ads on websites that cater to the 50+ population segment: “This new marketing program has been designed to increase awareness and promote direct to consumer sales from our online store.” added Doederlein.
HealthSonix, Inc. (OTC:HSXI - News)(FWB:H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The company’s patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Contact:
for HealthSonix, Inc.
Dieter Doederlein, 1-877-622-2121 x112
--------------------------------------------------
Source: HealthSonix, Inc.
IRVINE, Calif.--(BUSINESS WIRE)--HealthSonix Inc. (OTC:HSXI) (FRANKFURT:H7S) today announced that it is has approved the final sample of its second generation enSonix medical device. Shipments of finished product are expected to commence in the second quarter.
The enSonix personal treatment device has been registered and cleared with the United States, Food and Drug Administration (FDA), and has been designated as a class1 device, the safest classification for medical devices. It has been indicated for pain reduction and muscle relaxation.
“With this new medical device, we offer our customers affordable, effective arthritis pain relief without side effects. Patients can use it in the comfort of their own homes. The enSonix therapy is especially effective when used in combination with the most popular pain relievers. There is an incremental therapeutic benefit when you combine therapies,” said Dieter Doederlein, Vice President of Corporate Development. “Arthritis is still the number one cause of chronic pain in North America and the HealthSonix breakthrough medical technology is very timely as the population segment most susceptible to arthritis will double over the next 20 years.”
The sound pressure waves generated by the enSonix medical device are believed to work in three ways: they stimulate mechanoreceptors in the skin, which in turn communicate with the brain and block pain messages from getting through (gate control theory of pain); they create an exercise effect in the muscles, which encourages the production and release of endorphins, the body's natural pain killers; and increase in blood circulation.
“Our objective is very clear; deliver as much product this year as we can to fulfill significant order back log that has been created over the past 12 months and to focus on development and expansion of distribution and sales channels for all of our consumer products,” added Mr. Doederlein.
HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The company’s patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
The enSonix personal treatment device has been registered and cleared with the United States, Food and Drug Administration (FDA), and has been designated as a class1 device, the safest classification for medical devices. It has been indicated for pain reduction and muscle relaxation.
“With this new medical device, we offer our customers affordable, effective arthritis pain relief without side effects. Patients can use it in the comfort of their own homes. The enSonix therapy is especially effective when used in combination with the most popular pain relievers. There is an incremental therapeutic benefit when you combine therapies,” said Dieter Doederlein, Vice President of Corporate Development. “Arthritis is still the number one cause of chronic pain in North America and the HealthSonix breakthrough medical technology is very timely as the population segment most susceptible to arthritis will double over the next 20 years.”
The sound pressure waves generated by the enSonix medical device are believed to work in three ways: they stimulate mechanoreceptors in the skin, which in turn communicate with the brain and block pain messages from getting through (gate control theory of pain); they create an exercise effect in the muscles, which encourages the production and release of endorphins, the body's natural pain killers; and increase in blood circulation.
“Our objective is very clear; deliver as much product this year as we can to fulfill significant order back log that has been created over the past 12 months and to focus on development and expansion of distribution and sales channels for all of our consumer products,” added Mr. Doederlein.
HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The company’s patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
HealthSonix Gives Green Light for Production of the enSonix Medical Device
16:40 11.02.08
IRVINE, Calif.--(BUSINESS WIRE)--
HealthSonix Inc. (OTC:HSXI) (FRANKFURT:H7S) today announced that it is has approved the final sample of its second generation enSonix medical device. Shipments of finished product are expected to commence in the second quarter.
The enSonix personal treatment device has been registered and cleared with the United States, Food and Drug Administration (FDA), and has been designated as a class1 device, the safest classification for medical devices. It has been indicated for pain reduction and muscle relaxation.
With this new medical device, we offer our customers affordable, effective arthritis pain relief without side effects. Patients can use it in the comfort of their own homes. The enSonix therapy is especially effective when used in combination with the most popular pain relievers. There is an incremental therapeutic benefit when you combine therapies, said Dieter Doederlein, Vice President of Corporate Development. Arthritis is still the number one cause of chronic pain in North America and the HealthSonix breakthrough medical technology is very timely as the population segment most susceptible to arthritis will double over the next 20 years.
The sound pressure waves generated by the enSonix medical device are believed to work in three ways: they stimulate mechanoreceptors in the skin, which in turn communicate with the brain and block pain messages from getting through (gate control theory of pain); they create an exercise effect in the muscles, which encourages the production and release of endorphins, the body's natural pain killers; and increase in blood circulation.
Our objective is very clear; deliver as much product this year as we can to fulfill significant order back log that has been created over the past 12 months and to focus on development and expansion of distribution and sales channels for all of our consumer products, added Mr. Doederlein.
HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The companys patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
(c)2007 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein
16:40 11.02.08
IRVINE, Calif.--(BUSINESS WIRE)--
HealthSonix Inc. (OTC:HSXI) (FRANKFURT:H7S) today announced that it is has approved the final sample of its second generation enSonix medical device. Shipments of finished product are expected to commence in the second quarter.
The enSonix personal treatment device has been registered and cleared with the United States, Food and Drug Administration (FDA), and has been designated as a class1 device, the safest classification for medical devices. It has been indicated for pain reduction and muscle relaxation.
With this new medical device, we offer our customers affordable, effective arthritis pain relief without side effects. Patients can use it in the comfort of their own homes. The enSonix therapy is especially effective when used in combination with the most popular pain relievers. There is an incremental therapeutic benefit when you combine therapies, said Dieter Doederlein, Vice President of Corporate Development. Arthritis is still the number one cause of chronic pain in North America and the HealthSonix breakthrough medical technology is very timely as the population segment most susceptible to arthritis will double over the next 20 years.
The sound pressure waves generated by the enSonix medical device are believed to work in three ways: they stimulate mechanoreceptors in the skin, which in turn communicate with the brain and block pain messages from getting through (gate control theory of pain); they create an exercise effect in the muscles, which encourages the production and release of endorphins, the body's natural pain killers; and increase in blood circulation.
Our objective is very clear; deliver as much product this year as we can to fulfill significant order back log that has been created over the past 12 months and to focus on development and expansion of distribution and sales channels for all of our consumer products, added Mr. Doederlein.
HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The companys patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
(c)2007 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein
das wird wohl bis zum 1. Finanzbericht dauern, wann der genau vorgelegt wird, weiss noch keiner.
@bafin: ich weiss nicht, was du willst, aber ZingiberRX Salbe hat mit Zink nichts zu tun. Ansonsten halte dich mit deinen albernen Sprüchen hier raus. Zur Sicherheit kommst du auf Ignore, ist ja mein Thread und du kannst mit deinesgleichen spielen, falls es noch mehr ID's auf diesem Niveau gibt - hehehe.
@bafin: ich weiss nicht, was du willst, aber ZingiberRX Salbe hat mit Zink nichts zu tun. Ansonsten halte dich mit deinen albernen Sprüchen hier raus. Zur Sicherheit kommst du auf Ignore, ist ja mein Thread und du kannst mit deinesgleichen spielen, falls es noch mehr ID's auf diesem Niveau gibt - hehehe.
HealthSonix Announces ZingiberRx Joint and Muscle Cream Marketing Program Soaring
Wednesday February 27, 11:14 am ET
IRVINE, Calif.--(BUSINESS WIRE)--HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) today announced that the multi-faceted marketing program for ZingiberRx Joint and Muscle Cream launched earlier this month is hitting stride and exceeding company expectations. The program consisted of launching the website, sampling, direct to consumer sales, test markets in retail stores, and advertising on Google search engines.
“Yesterday alone, we had over 5,300 visits to our website and received over 5,000 requests for samples,“ said Dieter D. Doederlein, Vice President of Corporate Development for HealthSonix. “This is significant because early evidence suggests that we have a high conversion rate from sample to purchase, and we continue to get positive feedback from users of all ages.”
“In addition to the direct to consumer marketing efforts, we have been test marketing the product in regional drug stores and have now progressed to Vendor status with one of the largest national drug store chains in Canada. ZingiberRx is actually the number one selling topical pain reliever in many of the early test locations and we have the full support and participation of the pharmacists when it comes to explaining the product and its benefits,” added Doederlein.
“The response to this new pain relieving cream, the first of its kind with ginger, is just short of amazing. It is really rewarding to witness the instant acceptance of ZingiberRx for the relief of pain and inflammation.”
ZingiberRx joint and muscle cream is fast acting, non-staining, fast absorbing, and deep penetrating. Unlike most over-the-counter topical ointments, ZingiberRx is not a counter-irritant and does not create a hot or a cold sensation when applied.
Medical research studies into the medicinal properties of various plants in the ginger (Zingiberaceae) family have isolated the Zingiber cassumunar species for its anti-inflammatory, anti-allergic and pain relieving properties.
HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The company’s patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Contact:
HealthSonix, Inc.
Dieter D. Doederlein, 905-212-7711
Wednesday February 27, 11:14 am ET
IRVINE, Calif.--(BUSINESS WIRE)--HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) today announced that the multi-faceted marketing program for ZingiberRx Joint and Muscle Cream launched earlier this month is hitting stride and exceeding company expectations. The program consisted of launching the website, sampling, direct to consumer sales, test markets in retail stores, and advertising on Google search engines.
“Yesterday alone, we had over 5,300 visits to our website and received over 5,000 requests for samples,“ said Dieter D. Doederlein, Vice President of Corporate Development for HealthSonix. “This is significant because early evidence suggests that we have a high conversion rate from sample to purchase, and we continue to get positive feedback from users of all ages.”
“In addition to the direct to consumer marketing efforts, we have been test marketing the product in regional drug stores and have now progressed to Vendor status with one of the largest national drug store chains in Canada. ZingiberRx is actually the number one selling topical pain reliever in many of the early test locations and we have the full support and participation of the pharmacists when it comes to explaining the product and its benefits,” added Doederlein.
“The response to this new pain relieving cream, the first of its kind with ginger, is just short of amazing. It is really rewarding to witness the instant acceptance of ZingiberRx for the relief of pain and inflammation.”
ZingiberRx joint and muscle cream is fast acting, non-staining, fast absorbing, and deep penetrating. Unlike most over-the-counter topical ointments, ZingiberRx is not a counter-irritant and does not create a hot or a cold sensation when applied.
Medical research studies into the medicinal properties of various plants in the ginger (Zingiberaceae) family have isolated the Zingiber cassumunar species for its anti-inflammatory, anti-allergic and pain relieving properties.
HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The company’s patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Contact:
HealthSonix, Inc.
Dieter D. Doederlein, 905-212-7711
HealthSonix to Conduct Clinical Trials with ZingiberRx for Complex Regional Pain Syndrome (CRPS)
Wednesday March 12, 9:43 am ET
IRVINE, Calif.--(BUSINESS WIRE)--HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) today announced that it has strong evidence that ZingiberRx Joint and Muscle Cream with ginger oil can provide pain relief for people with Complex Regional Pain Syndrome (CRPS), also referred to as Reflex Sympathetic Dystrophy (RSD).
The main symptom of CRPS is intense chronic pain, often described as ‘burning’ pain. Additional signs and symptoms include localized swelling; changes in skin temperature and color; joint stiffness; muscle spasms, weakness and loss (atrophy); and decreased range of motion.
“We have been testing ZingiberRx with a CRPS group and the on-going positive feedback we get from the participants has led to the decision to conduct a formal scientific study for this condition,” said Dieter D. Doederlein, Vice President Corporate Development for HealthSonix.
“Members of our St Catharines CRPS support group had excellent outcomes from the ZingiberRx samples you provided. You definitely should consider a clinical trial,” said Helen Small, President of PARC, a national support group that is Promoting Awareness of RSD and CRPS in Canada.
“According to the Mayo Clinic, many cases of complex regional pain syndrome occur after a forceful trauma to an arm or a leg, as a result of motor vehicle accidents, shrapnel blasts and other traumas - such as surgery, heart attacks, infections, fractures and sprained ankles. This could open up a whole new market for ZingiberRx,” added Doederlein.
HealthSonix, Inc. (OTC: HSXI)(FWB: H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The company’s patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Contact:
HealthSonix, Inc.
Dieter Doederlein, 877-622-2121
--------------------------------------------------
Source: HealthSonix, Inc.
Wednesday March 12, 9:43 am ET
IRVINE, Calif.--(BUSINESS WIRE)--HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) today announced that it has strong evidence that ZingiberRx Joint and Muscle Cream with ginger oil can provide pain relief for people with Complex Regional Pain Syndrome (CRPS), also referred to as Reflex Sympathetic Dystrophy (RSD).
The main symptom of CRPS is intense chronic pain, often described as ‘burning’ pain. Additional signs and symptoms include localized swelling; changes in skin temperature and color; joint stiffness; muscle spasms, weakness and loss (atrophy); and decreased range of motion.
“We have been testing ZingiberRx with a CRPS group and the on-going positive feedback we get from the participants has led to the decision to conduct a formal scientific study for this condition,” said Dieter D. Doederlein, Vice President Corporate Development for HealthSonix.
“Members of our St Catharines CRPS support group had excellent outcomes from the ZingiberRx samples you provided. You definitely should consider a clinical trial,” said Helen Small, President of PARC, a national support group that is Promoting Awareness of RSD and CRPS in Canada.
“According to the Mayo Clinic, many cases of complex regional pain syndrome occur after a forceful trauma to an arm or a leg, as a result of motor vehicle accidents, shrapnel blasts and other traumas - such as surgery, heart attacks, infections, fractures and sprained ankles. This could open up a whole new market for ZingiberRx,” added Doederlein.
HealthSonix, Inc. (OTC: HSXI)(FWB: H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The company’s patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Contact:
HealthSonix, Inc.
Dieter Doederlein, 877-622-2121
--------------------------------------------------
Source: HealthSonix, Inc.
die SEC hat einen Verdacht auf Unregelmässigkeiten bei der Mantelübernahme von 26 OTC-Firmen. Das hat nichts mit dem Geschäftsbetrieb von HSXI ansich zu tun. Wer und was im Falle HSXI gelaufen ist, werden wir sehen.
Jedenfalls wurde ich in 2 Fällen von OTC Firmen mein Geld los, dort hatten die Manager ganz klar falsche PR's ausgegeben und einige US-Investoren sogar die SEC informiert. Da ist nichts passiert, obwohl da manipuliert wurde.
HSXI hat Produkte entwickelt und diese kann man kaufen, die sind sogar sehr wirksam, habe ich selber getestet. Betrüger machen so etwas nicht, die wollen nur Aktien verkaufen, solange es geht. Die SEC will sich nur profilieren in dem ganzen Finanzchaos der US-Banken.
Jedenfalls wurde ich in 2 Fällen von OTC Firmen mein Geld los, dort hatten die Manager ganz klar falsche PR's ausgegeben und einige US-Investoren sogar die SEC informiert. Da ist nichts passiert, obwohl da manipuliert wurde.
HSXI hat Produkte entwickelt und diese kann man kaufen, die sind sogar sehr wirksam, habe ich selber getestet. Betrüger machen so etwas nicht, die wollen nur Aktien verkaufen, solange es geht. Die SEC will sich nur profilieren in dem ganzen Finanzchaos der US-Banken.
Es gibt keine neuen Beiträge.
Der Thread wurde geschlossen.
|
Neueste Beiträge aus dem HealthSonix Inc Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 109 | HEALTHSONIX INC. mit gesundem Verstand anlegen. | buran | RPM1974 | 25.05.10 13:46 | ||
7 | 888 | Healthsonix Inc. DL-,001 | Limitless | RPM1974 | 30.03.08 20:08 | |
| 69 | 16:40 11.02.08 | buran | Matzelbub | 15.03.08 18:34 |